Title of article
Good Clinical Response to Erlotinib in a Lung Adenocancer Patient and Grade 3 Skin Rash: A Case Report
Author/Authors
Karaca, Halit Erciyes University - Faculty of Medicine - Department of Medical Oncology, Turkey , Lale, Ayhan Erciyes University - Faculty of Medicine - Department of Internal Medicine, Turkey , Dikilitas, Mustafa Erciyes University - Faculty of Medicine - Department of Medical Oncology, Turkey , Berk, Veli Erciyes University - Faculty of Medicine - Department of Medical Oncology, Turkey , Özkan, Metin Erciyes University - Faculty of Medicine - Department of Medical Oncology, Turkey , Er, Özlem Erciyes University - Faculty of Medicine - Department of Medical Oncology, Turkey
From page
145
To page
148
Abstract
Epidermal growth factor receptor (EGFR) has received a particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase (EGFR-TKI), hasbeen proven to prolong survival in non-small cell lung cancer (NSCLC) patients after first or second line chemotherapy. Skin rash is the most common adverse event associated with erlotinib treatment and a significant correlation between severity of rash and survival has been found. We report a case of lung adenocancer that we obtain good response together with severe skin rash by erlotinib therapy.
Keywords
Drug Eruptions , Erlotinib , Lung Neoplasms , Receptor Protein , Tyrosine Kinases
Journal title
Erciyes Medical Journal
Journal title
Erciyes Medical Journal
Record number
2597152
Link To Document